AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37839434 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation
Number of subjects: 412
Study 37839434 — intervention group
Group type: COMPARATOR
Intervention: Avoiding oral anticoagulation (control)
Number of subjects: 412
Study 37839506 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured model of care including 3-hour patient education and 8-12 weeks individually tailored exercise programs
Number of subjects: 393
Study 37839506 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured model of care
Number of subjects: 393
Study 37839506 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 393
Study 37839546 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet intervention
Number of subjects: 692
Study 37839546 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-based stress reduction program
Number of subjects: 692
Study 37839546 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 692
Study 37839573 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma fibrinogen (FIB) level
Number of subjects: 587
Study 37839573 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 587
Study 37839573 — intervention group
Group type: EXPERIMENTAL
Intervention: High admission pulse rate
Number of subjects: 587
Study 37839573 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma FIB level
Number of subjects: 587
Study 37839707 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (400 mg/d)
Number of subjects: 314
Study 37839707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 37839894 — intervention group
Group type: EXPERIMENTAL
Intervention: Chidamide plus prednisone, cyclophosphamide, and thalidomide (CPCT) regimen
Number of subjects: 45
Study 37839923 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset diabetes in participants without diabetes at enrollment
Number of subjects: 98
Study 37839958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) - 10 weekly sessions of 120 minutes each
Number of subjects: 60
Study 37839958 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study 37840055 — intervention group
Group type: EXPERIMENTAL
Intervention: MY-RADS protocol for WB-MRI
Number of subjects: 121
Study 37840095 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 0
Study 37840095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37840107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous HPV types 27, 57, and 2
Number of subjects: 269
Study 37840107 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent warts
Number of subjects: 269
Study 37840107 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load quantification
Number of subjects: 269
Study 37840107 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 269
Study 37840119 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab (900 mg, single intravenous dose on day 1)
Number of subjects: 11
Study 37840119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 37840119 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab
Number of subjects: 11
Study 37840134 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab 200 mg (SAR200 + 26W)
Number of subjects: 83
Study 37840134 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab 150 mg (SAR150 + 26W)
Number of subjects: 83
Study 37840134 — intervention group
Group type: COMPARATOR
Intervention: placebo with 52-week GC taper (PBO + 52W)
Number of subjects: 83
Study 37840134 — intervention group
Group type: COMPARATOR
Intervention: placebo with 26-week GC taper (PBO + 26W)
Number of subjects: 83
Study 37840134 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 83
Study 37840155 — intervention group
Group type: EXPERIMENTAL
Intervention: Danuglipron (20 mg)
Number of subjects: 39
Study 37840504 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous music-based digital walking intervention (30-minute sessions, 5 times a week for 4 weeks)
Number of subjects: 23
Study 37840504 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous music-based digital walking intervention
Number of subjects: 23
Study 37840530 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib monotherapy
Number of subjects: 106
Study 37840530 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus LY3023414
Number of subjects: 106
Study 37840530 — intervention group
Group type: COMPARATOR
Intervention: SOC chemotherapy (gemcitabine or capecitabine)
Number of subjects: 106
Study 37840634 — intervention group
Group type: EXPERIMENTAL
Intervention: HASBLED
Number of subjects: 7613
Study 37840634 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRIA
Number of subjects: 7613
Study 37840634 — intervention group
Group type: EXPERIMENTAL
Intervention: ORBIT
Number of subjects: 7613
Study 37840634 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding (MB)
Number of subjects: 7613
Study 37840634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhage (ICH)
Number of subjects: 7613
Study 37840766 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream applied to lesions once or twice daily for 52 weeks
Number of subjects: 57
Study 37840766 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (not explicitly detailed in the abstract)
Number of subjects: 57
Study 37840952 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation patients
Number of subjects: 199433
Study 37840952 — intervention group
Group type: COMPARATOR
Intervention: Age-and sex matched controls
Number of subjects: 199433
Study 37841423 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (AI)
Number of subjects: 961
Study 37841423 — intervention group
Group type: COMPARATOR
Intervention: Aromatase inhibitor (AI) alone
Number of subjects: 961
Study 37841441 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant intraperitoneal and systemic (NIPS) albumin-bound paclitaxel combined with Camrelizumab and S-1
Number of subjects: 0
Study 37841647 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic digital intervention including personalized recommendations for diet, physical activity, sleep, and stress management.
Number of subjects: 56
Study 37841647 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 56
Study 37841869 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring Contact letters sent by CareSource
Number of subjects: 43000
Study 37841869 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 43000
Study 37841873 — intervention group
Group type: EXPERIMENTAL
Intervention: Click-decoding using a chronically implanted high density electrocorticographic (ECoG) BCI
Number of subjects: 1
Study 37841873 — intervention group
Group type: EXPERIMENTAL
Intervention: New click decoder trained with < 15 min of data
Number of subjects: 1
Study 37841877 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-based graph-theoretical predictive model (GPM)
Number of subjects: 80
Study 37841877 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-based graph-theoretical predictive model (GPM) derived from individuals with unipolar disorders
Number of subjects: 80
Study 37842200 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) combined with fruquintinib and tislelizumab
Number of subjects: 68
Study 37842323 — intervention group
Group type: EXPERIMENTAL
Intervention: shen-based qigong exercise intervention along with daily rehabilitation
Number of subjects: 60
Study 37842323 — intervention group
Group type: COMPARATOR
Intervention: daily rehabilitation
Number of subjects: 60
Study 37842322 — intervention group
Group type: EXPERIMENTAL
Intervention: Deimplementation strategy
Number of subjects: 0
Study 37842523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic shears
Number of subjects: 40
Study 37842523 — intervention group
Group type: COMPARATOR
Intervention: Advanced bipolar device
Number of subjects: 40
Study 37842826 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory interventions
Number of subjects: 172
Study 37842826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 37843101 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening for ovarian cancer (over 670,000 yearly screens from 2001-2011)
Number of subjects: 202000
Study 37843101 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive electronic trial management system
Number of subjects: 202000
Study 37843101 — intervention group
Group type: EXPERIMENTAL
Intervention: Automation of eligibility checks and appointment scheduling
Number of subjects: 202000
Study 37843478 — intervention group
Group type: EXPERIMENTAL
Intervention: Instability
Number of subjects: 360
Study 37843478 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma
Number of subjects: 360
Study 37843629 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal for at least 48 hours
Number of subjects: 412
Study 37843629 — intervention group
Group type: COMPARATOR
Intervention: Ventilation alone
Number of subjects: 412
Study 37843637 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD application (EMD+)
Number of subjects: 22
Study 37843637 — intervention group
Group type: COMPARATOR
Intervention: Subgingival instrumentation without EMD (EMD-)
Number of subjects: 22
Study 37843637 — intervention group
Group type: COMPARATOR
Intervention: Comparison of EMD+ and EMD-
Number of subjects: 22
Study 37843770 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified clinical screening model for predicting GDM risk
Number of subjects: 1289
Study 37843770 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression model
Number of subjects: 1289
Study 37843770 — intervention group
Group type: COMPARATOR
Intervention: Comparison with three other published models
Number of subjects: 1289
Study 37843770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootstrapping for internal validation
Number of subjects: 1289
Study 37843770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hosmer-Lemeshow goodness-of-fit test
Number of subjects: 1289
Study 37843771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 0
Study 37843771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0
Study 37843771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0
Study 37843771 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 0
Study 37843771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg, 10 mg, 15 mg
Number of subjects: 0
Study 37843772 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-sized allogeneic serum eye drops (7 µl/unit)
Number of subjects: 49
Study 37843772 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-sized allogeneic serum eye drops (50 µl/unit)
Number of subjects: 49
Study 37843772 — intervention group
Group type: COMPARATOR
Intervention: User-friendliness of conventional drop system
Number of subjects: 49
Study 37843843 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation (400 mg/d for 6 weeks)
Number of subjects: 28
Study 37843843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 37843910 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 0
Study 37844137 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVAL self-expandable paclitaxel drug-eluting stent (DES)
Number of subjects: 201
Study 37844137 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA) with an uncoated balloon
Number of subjects: 201
Study 37844320 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorohexyloctane (PFHO) ophthalmic solution (MIEBO™; Bausch + Lomb)
Number of subjects: 0
Study 37844320 — intervention group
Group type: COMPARATOR
Intervention: Saline eye drops
Number of subjects: 0
Study 37844519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral Blood Flow (CBF) measurement using jugular venous flow
Number of subjects: 27
Study 37844519 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic-Pulmonary Collateral (APC) flow measurement
Number of subjects: 27
Study 37844519 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Injury (BI) assessment (focal BI, generalized insult, and hemorrhage)
Number of subjects: 27
Study 37844597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy (240 mg IV every 2 weeks)
Number of subjects: 207
Study 37844597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (3 mg/kg and 1 mg/kg respectively) boosts
Number of subjects: 207
Study 37844597 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab plus ipilimumab
Number of subjects: 207
Study 37844598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenous once every 3 weeks plus lenvatinib 20 mg oral once per day for up to 2 years or until disease progression, development of unacceptable toxicity, or withdrawal of consent.
Number of subjects: 38
Study 37844796 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure mechanical insufflation-exsufflation (HP-MIE)
Number of subjects: 29
Study 37844796 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure mechanical insufflation-exsufflation (LP-MIE)
Number of subjects: 29
Study 37844838 — intervention group
Group type: COMPARATOR
Intervention: 36 h fasting
Number of subjects: 74
Study 37844838 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose administration
Number of subjects: 74
Study 37844838 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucose administration
Number of subjects: 74
Study 37844838 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lactate administration
Number of subjects: 74
Study 37844838 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lactate administration
Number of subjects: 74
Study 37844838 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Na-β-hydroxybutyrate (BHB) administration
Number of subjects: 74
Study 37844838 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Na-β-hydroxybutyrate (BHB) administration
Number of subjects: 74
Study 37844986 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA group (oxycodone: 0.5 mg/kg)
Number of subjects: 160
Study 37844986 — intervention group
Group type: EXPERIMENTAL
Intervention: OCB group (oxycodone: 1.0 mg/kg)
Number of subjects: 160
Study 37844986 — intervention group
Group type: EXPERIMENTAL
Intervention: OCC group (oxycodone: 1.5 mg/kg)
Number of subjects: 160
Study 37844986 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil group (sufentanil: 2 µg/kg)
Number of subjects: 160
Study 37844986 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including flurbiprofen 50 mg and ondansetron 16 mg)
Number of subjects: 160
Study 37844986 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 160
Study 37844988 — intervention group
Group type: EXPERIMENTAL
Intervention: Online screening of HIV and STIs with self-sampling kits; participants alternate face-to-face meetings with online screening.
Number of subjects: 0
Study 37844988 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up protocol with quarterly face-to-face visits for HIV and STI testing.
Number of subjects: 0
Study 37844988 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptability of the intervention among participants and healthcare workers.
Number of subjects: 0
Study 37845108 — intervention group
Group type: EXPERIMENTAL
Intervention: In-cabin tracheal intubation
Number of subjects: 422
Study 37845108 — intervention group
Group type: COMPARATOR
Intervention: Outside cabin tracheal intubation
Number of subjects: 422
Study 37845427 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab (2×2.5 g/50 ml) in group A
Number of subjects: 804
Study 37845427 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab (2×2.5 g/50 ml) in group B
Number of subjects: 804
Study 37845502 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) glasses
Number of subjects: 40
Study 37845502 — intervention group
Group type: COMPARATOR
Intervention: Audio (vocal-guided affective imagery)
Number of subjects: 40
Study 37845511 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg every 4 weeks for 12 months
Number of subjects: 790
Study 37845511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 790
Study 37845511 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg
Number of subjects: 790
Study 37845511 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 790
Study 37845512 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg resmetirom
Number of subjects: 1143
Study 37845512 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg resmetirom
Number of subjects: 1143
Study 37845512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1143
Study 37845512 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label 100 mg resmetirom
Number of subjects: 1143
Study 37845588 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW telehealth intervention (5 virtual group-based health education sessions, an action plan, and follow-up calls)
Number of subjects: 190
Study 37845588 — intervention group
Group type: COMPARATOR
Intervention: Control group (only the first session)
Number of subjects: 190
Study 37845603 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous cognitive-exercise training (SCET)
Number of subjects: 106
Study 37845604 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) angioplasty
Number of subjects: 84
Study 37845604 — intervention group
Group type: COMPARATOR
Intervention: Plain old balloon (POB) dilatation
Number of subjects: 84
Study 37845608 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant glycoprotein E subunit herpes zoster vaccine (RZV)
Number of subjects: 875
Study 37845612 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of 0.2 ml colostrum every 3 hours for 5 consecutive days.
Number of subjects: 320
Study 37845612 — intervention group
Group type: COMPARATOR
Intervention: Oropharyngeal administration of sterile water (control group).
Number of subjects: 320
Study 37845624 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause in-hospital mortality
Number of subjects: 35000
Study 37845624 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission to intensive care unit
Number of subjects: 35000
Study 37845624 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 35000
Study 37845624 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of hospitalisation
Number of subjects: 35000
Study 37845624 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of respiratory support required
Number of subjects: 35000
Study 37845696 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NI)
Number of subjects: 0
Study 37845696 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (pemetrexed plus cisplatin/carboplatin, C)
Number of subjects: 0
Study 37845752 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth gait retraining intervention with standard of care
Number of subjects: 0
Study 37845752 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 37845776 — intervention group
Group type: EXPERIMENTAL
Intervention: G-NoMAD questionnaire (German version)
Number of subjects: 539
Study 37846080 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 392
Study 37846080 — intervention group
Group type: COMPARATOR
Intervention: Investigator-chosen chemotherapy (paclitaxel, docetaxel, or irinotecan)
Number of subjects: 392
Study 37846437 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEW intervention (12-week resilience-building energy management program including an educational website/application and nine virtual peer-led health coaching sessions)
Number of subjects: 173
Study 37846437 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEW intervention
Number of subjects: 173
Study 37846437 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 173
Study 37846456 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-valent V114 (PCV15)
Number of subjects: 2
Study 37846456 — intervention group
Group type: COMPARATOR
Intervention: 20-valent PCV20
Number of subjects: 2
Study 37846462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 and 1.0 mg/kg)
Number of subjects: 31
Study 37846607 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 93
Study 37846607 — intervention group
Group type: EXPERIMENTAL
Intervention: ASV 1508 and ASV 664
Number of subjects: 93
Study 37846607 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota composition
Number of subjects: 93
Study 37846664 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 severity measured on a five-level ordinal scale
Number of subjects: 1383
Study 37846724 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 (Qdenga®), a live attenuated dengue tetravalent vaccine, administered during the second half of its 24-month shelf-life
Number of subjects: 0
Study 37846737 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-refugee immigrants with psychotic disorder
Number of subjects: 0
Study 37846737 — intervention group
Group type: COMPARATOR
Intervention: Native-born individuals with psychotic disorder
Number of subjects: 0
Study 37846737 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-refugee immigrants with psychosis
Number of subjects: 0
Study 37846769 — intervention group
Group type: EXPERIMENTAL
Intervention: POLARx cryoballoon system
Number of subjects: 125
Study 37846845 — intervention group
Group type: EXPERIMENTAL
Intervention: Early relapse within 18 months (ER18) after initial treatment
Number of subjects: 629
Study 37846845 — intervention group
Group type: EXPERIMENTAL
Intervention: Early relapse within 18 months (ER18)
Number of subjects: 629
Study 37846845 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic risk assessment
Number of subjects: 629
Study 37846935 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Oxygen (HFNO) treatment
Number of subjects: 696